Cargando…
Attrition when providing antiretroviral treatment at CD4 counts >500cells/μL at three government clinics included in the HPTN 071 (PopART) trial in South Africa
INTRODUCTION: WHO recommends antiretroviral treatment (ART) for all HIV-positive individuals. This study evaluated the association between baseline CD4 count and attrition in a cohort of HIV positive adults initiating ART at three department of health (DOH) clinics routinely providing ART at baselin...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909512/ https://www.ncbi.nlm.nih.gov/pubmed/29672542 http://dx.doi.org/10.1371/journal.pone.0195127 |
_version_ | 1783315914526031872 |
---|---|
author | Bock, Peter Fatti, Geoffrey Ford, Nathan Jennings, Karen Kruger, James Gunst, Colette Louis, Françoise Grobbelaar, Nelis Shanaube, Kwame Floyd, Sian Grimwood, Ashraf Hayes, Richard Ayles, Helen Fidler, Sarah Beyers, Nulda |
author_facet | Bock, Peter Fatti, Geoffrey Ford, Nathan Jennings, Karen Kruger, James Gunst, Colette Louis, Françoise Grobbelaar, Nelis Shanaube, Kwame Floyd, Sian Grimwood, Ashraf Hayes, Richard Ayles, Helen Fidler, Sarah Beyers, Nulda |
author_sort | Bock, Peter |
collection | PubMed |
description | INTRODUCTION: WHO recommends antiretroviral treatment (ART) for all HIV-positive individuals. This study evaluated the association between baseline CD4 count and attrition in a cohort of HIV positive adults initiating ART at three department of health (DOH) clinics routinely providing ART at baseline CD4 counts >500cells/μL for the HPTN 071 (PopART) trial. METHODS: All clients attending the DOH clinics were managed according to standard care guidelines with the exception that those starting ART outside of pertinent local guidelines signed research informed consent. DOH data on all HIV-positive adult clients recorded as having initiated ART between January 2014 and November 2015 at the three study clinics was analysed. Attrition, included clients lost to follow up or died, and was defined as ‘being three or more months late for an antiretroviral pharmacy pick-up appointment’. All clients were followed until attrition, transfer out or end May 2016. RESULTS: A total of 2423 clients with a median baseline CD4 count of 328 cells/μL (IQR 195–468) were included of whom 631 (26.0%) experienced attrition and 140 (5.8%) were TFO. Attrition was highest during the first six months of ART (IR 38.3/100 PY; 95% CI 34.8–42.1). Higher attrition was found amongst those with baseline CD4 counts > 500 cells/μL compared to those with baseline CD4 counts of 0–500 cells/μL (aHR 1.26, 95%CI 1.05 to 1.52) This finding was confirmed on subset analyses when restricted to individuals non-pregnant at baseline and when restricted to individuals with follow up of > 12months. CONCLUSIONS: Attrition in this study was high, particularly during the first six months of treatment. Attrition was highest amongst clients starting ART at baseline CD4 counts > 500 cells/μL. Strategies to improve retention amongst ART clients, particularly those starting ART at baseline CD4 counts >500cells/μL, need strengthening. Improved monitoring of clients moving in and out of ART care and between clinics will assist in better understanding attrition and ART coverage in high burden countries. |
format | Online Article Text |
id | pubmed-5909512 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-59095122018-05-05 Attrition when providing antiretroviral treatment at CD4 counts >500cells/μL at three government clinics included in the HPTN 071 (PopART) trial in South Africa Bock, Peter Fatti, Geoffrey Ford, Nathan Jennings, Karen Kruger, James Gunst, Colette Louis, Françoise Grobbelaar, Nelis Shanaube, Kwame Floyd, Sian Grimwood, Ashraf Hayes, Richard Ayles, Helen Fidler, Sarah Beyers, Nulda PLoS One Research Article INTRODUCTION: WHO recommends antiretroviral treatment (ART) for all HIV-positive individuals. This study evaluated the association between baseline CD4 count and attrition in a cohort of HIV positive adults initiating ART at three department of health (DOH) clinics routinely providing ART at baseline CD4 counts >500cells/μL for the HPTN 071 (PopART) trial. METHODS: All clients attending the DOH clinics were managed according to standard care guidelines with the exception that those starting ART outside of pertinent local guidelines signed research informed consent. DOH data on all HIV-positive adult clients recorded as having initiated ART between January 2014 and November 2015 at the three study clinics was analysed. Attrition, included clients lost to follow up or died, and was defined as ‘being three or more months late for an antiretroviral pharmacy pick-up appointment’. All clients were followed until attrition, transfer out or end May 2016. RESULTS: A total of 2423 clients with a median baseline CD4 count of 328 cells/μL (IQR 195–468) were included of whom 631 (26.0%) experienced attrition and 140 (5.8%) were TFO. Attrition was highest during the first six months of ART (IR 38.3/100 PY; 95% CI 34.8–42.1). Higher attrition was found amongst those with baseline CD4 counts > 500 cells/μL compared to those with baseline CD4 counts of 0–500 cells/μL (aHR 1.26, 95%CI 1.05 to 1.52) This finding was confirmed on subset analyses when restricted to individuals non-pregnant at baseline and when restricted to individuals with follow up of > 12months. CONCLUSIONS: Attrition in this study was high, particularly during the first six months of treatment. Attrition was highest amongst clients starting ART at baseline CD4 counts > 500 cells/μL. Strategies to improve retention amongst ART clients, particularly those starting ART at baseline CD4 counts >500cells/μL, need strengthening. Improved monitoring of clients moving in and out of ART care and between clinics will assist in better understanding attrition and ART coverage in high burden countries. Public Library of Science 2018-04-19 /pmc/articles/PMC5909512/ /pubmed/29672542 http://dx.doi.org/10.1371/journal.pone.0195127 Text en © 2018 Bock et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Bock, Peter Fatti, Geoffrey Ford, Nathan Jennings, Karen Kruger, James Gunst, Colette Louis, Françoise Grobbelaar, Nelis Shanaube, Kwame Floyd, Sian Grimwood, Ashraf Hayes, Richard Ayles, Helen Fidler, Sarah Beyers, Nulda Attrition when providing antiretroviral treatment at CD4 counts >500cells/μL at three government clinics included in the HPTN 071 (PopART) trial in South Africa |
title | Attrition when providing antiretroviral treatment at CD4 counts >500cells/μL at three government clinics included in the HPTN 071 (PopART) trial in South Africa |
title_full | Attrition when providing antiretroviral treatment at CD4 counts >500cells/μL at three government clinics included in the HPTN 071 (PopART) trial in South Africa |
title_fullStr | Attrition when providing antiretroviral treatment at CD4 counts >500cells/μL at three government clinics included in the HPTN 071 (PopART) trial in South Africa |
title_full_unstemmed | Attrition when providing antiretroviral treatment at CD4 counts >500cells/μL at three government clinics included in the HPTN 071 (PopART) trial in South Africa |
title_short | Attrition when providing antiretroviral treatment at CD4 counts >500cells/μL at three government clinics included in the HPTN 071 (PopART) trial in South Africa |
title_sort | attrition when providing antiretroviral treatment at cd4 counts >500cells/μl at three government clinics included in the hptn 071 (popart) trial in south africa |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909512/ https://www.ncbi.nlm.nih.gov/pubmed/29672542 http://dx.doi.org/10.1371/journal.pone.0195127 |
work_keys_str_mv | AT bockpeter attritionwhenprovidingantiretroviraltreatmentatcd4counts500cellsmlatthreegovernmentclinicsincludedinthehptn071poparttrialinsouthafrica AT fattigeoffrey attritionwhenprovidingantiretroviraltreatmentatcd4counts500cellsmlatthreegovernmentclinicsincludedinthehptn071poparttrialinsouthafrica AT fordnathan attritionwhenprovidingantiretroviraltreatmentatcd4counts500cellsmlatthreegovernmentclinicsincludedinthehptn071poparttrialinsouthafrica AT jenningskaren attritionwhenprovidingantiretroviraltreatmentatcd4counts500cellsmlatthreegovernmentclinicsincludedinthehptn071poparttrialinsouthafrica AT krugerjames attritionwhenprovidingantiretroviraltreatmentatcd4counts500cellsmlatthreegovernmentclinicsincludedinthehptn071poparttrialinsouthafrica AT gunstcolette attritionwhenprovidingantiretroviraltreatmentatcd4counts500cellsmlatthreegovernmentclinicsincludedinthehptn071poparttrialinsouthafrica AT louisfrancoise attritionwhenprovidingantiretroviraltreatmentatcd4counts500cellsmlatthreegovernmentclinicsincludedinthehptn071poparttrialinsouthafrica AT grobbelaarnelis attritionwhenprovidingantiretroviraltreatmentatcd4counts500cellsmlatthreegovernmentclinicsincludedinthehptn071poparttrialinsouthafrica AT shanaubekwame attritionwhenprovidingantiretroviraltreatmentatcd4counts500cellsmlatthreegovernmentclinicsincludedinthehptn071poparttrialinsouthafrica AT floydsian attritionwhenprovidingantiretroviraltreatmentatcd4counts500cellsmlatthreegovernmentclinicsincludedinthehptn071poparttrialinsouthafrica AT grimwoodashraf attritionwhenprovidingantiretroviraltreatmentatcd4counts500cellsmlatthreegovernmentclinicsincludedinthehptn071poparttrialinsouthafrica AT hayesrichard attritionwhenprovidingantiretroviraltreatmentatcd4counts500cellsmlatthreegovernmentclinicsincludedinthehptn071poparttrialinsouthafrica AT ayleshelen attritionwhenprovidingantiretroviraltreatmentatcd4counts500cellsmlatthreegovernmentclinicsincludedinthehptn071poparttrialinsouthafrica AT fidlersarah attritionwhenprovidingantiretroviraltreatmentatcd4counts500cellsmlatthreegovernmentclinicsincludedinthehptn071poparttrialinsouthafrica AT beyersnulda attritionwhenprovidingantiretroviraltreatmentatcd4counts500cellsmlatthreegovernmentclinicsincludedinthehptn071poparttrialinsouthafrica AT attritionwhenprovidingantiretroviraltreatmentatcd4counts500cellsmlatthreegovernmentclinicsincludedinthehptn071poparttrialinsouthafrica |